BioAtla Q3 net loss narrows to $10.6M on $11M collaboration revenue; cash runway into early 2026

BioAtla, Inc.

2024-Q3 EPS reported -$1.14

Q3 net loss $10.6M vs $33.3M in Q3 2023; R&D expenses fell to $16.4M from $28.4M.
Cash and equivalents $56.5M at Sept 30, 2024, down from $111.5M at Dec 31, 2023.
Ozuriftamab vedotin (CAB-ROR2-ADC) shows median OS ~9 months in heavily pretreated SCCHN; FDA supported pivotal trial design.
Evalstotug (CAB-CTLA-4) + PD-1 produced tumor reduction in all 8 first-line melanoma patients, with 1 CR and 3 PRs.
Worldwide license agreement for CAB-Nectin-4 TCE with Context Therapeutics for up to $133.5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.